Information Provided By:
Fly News Breaks for November 5, 2019
ALV, BYND, AMGN, FB, NXPI
Nov 5, 2019 | 10:09 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Outperform at Daiwa with analyst Satoshi Tanaka saying the company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns." 2. Beyond Meat (BYND) upgraded to Outperform from Market Perform at Bernstein with analyst Alexia Howard saying she is making a "straightforward valuation call" with the shares down 66% from their peak. 3. NXP Semiconductors (NXPI) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying the company's auto segment is showing signs of recovery, with easier compares and content wins. 4. Amgen (AMGN) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Alethia Young saying recent events have set the stage for a "clean base business and pipeline story" for Amgen in 2020. 5. Autoliv (ALV) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying an improving 2020-2021 auto outlook with easier compares, continued airbag market share gains versus Takata, and lower product launch costs position Autoliv well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
News For FB;BYND;NXPI;AMGN;ALV From the Last 2 Days
FB
Nov 18, 2019 | 14:01 EST
Call volume jumps in Facebook as shares and implied volatility lift. Notable pickup in action at 1:20PM ET today with 18K calls trading in ten minutes, vs 3300 puts, as shares lifted $1 to $196.29 in heavy volume. At the same time 30day atmiv lifted a point to 23.7%. Nearly 45% of today's volume is weeklys that expire this Friday, including the top four most actives, upside calls in the 195 to 205 strike range. chart
AMGN
Nov 18, 2019 | 09:11 EST
Amgen (AMGN), Cytokinetics (CYTK) and Servier announced that new results from COSMIC-HF, a Phase 2 trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, will be presented today at the American Heart Association's Scientific Sessions 2019 in Philadelphia. In patients with HFrEF treated with omecamtiv mecarbil, in addition to previously reported improvements in cardiac contractility measures, measures of diastolic function were not different from placebo and, for some measures, trended towards improvement. In COSMIC-HF, 448 patients with stable, symptomatic heart failure and left ventricular ejection fraction less than40% were randomly assigned to omecamtiv mecarbil or placebo in a double-blind fashion for 20 weeks. This post-hoc analysis assessed the effect of chronic therapy with omecamtiv mecarbil by treatment group on echocardiographic measures of diastolic function, including early and late peak mitral inflow velocities, early peak myocardial relaxation velocity, isovolumic relaxation time, tricuspid regurgitation velocity and diastolic filling time. In patients with HFrEF who received omecamtiv mecarbil, systolic ejection time increased as previously reported and expected, while diastolic filling time was not reduced, nor were diastolic parameters worsened. Specifically, in patients receiving omecamtiv mecarbil E-wave velocity, E/A-ratio, and E/e' or e' were not significantly changed compared to placebo. There was a small increase in the duration of the IVRT, and in the PK group, TRV, an indicator of pulmonary pressure, improved significantly during treatment with omecamtiv mecarbil therapy
AMGN
Nov 18, 2019 | 09:05 EST
Amgen (AMGN), Cytokinetics (CYTK) and Servier announced that new results from COSMIC-HF, a Phase 2 trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, will be presented at the American Heart Association's Scientific Sessions 2019 in Philadelphia. In patients with HFrEF treated with omecamtiv mecarbil, in addition to previously reported improvements in cardiac contractility measures (including systolic function, or pumping action of the heart), measures of diastolic function were not different from placebo and, for some measures, trended towards improvement. "The results show that, in addition to increasing the pumping action of the heart, omecamtiv mecarbil did not change and for some measures was consistent with improvement of the heart's diastolic function, or ability to relax between heartbeats," said Tor Biering-Sorensen, M.D., Herlev & Gentofte Hospital and Associate Professor, University of Copenhagen, who will present the data at AHA. In COSMIC-HF, 448 patients with stable, symptomatic heart failure and left ventricular ejection fraction less than40% were randomly assigned to omecamtiv mecarbil; or 25 mg twice daily with pharmacokinetic-guided dose selection to 50 mg twice daily or placebo in a double-blind fashion for 20 weeks. This post-hoc analysis assessed the effect of chronic therapy with omecamtiv mecarbil by treatment group on echocardiographic measures of diastolic function, including early and late peak mitral inflow velocities, early peak myocardial relaxation velocity, isovolumic relaxation time, tricuspid regurgitation velocity and diastolic filling time. In patients with HFrEF who received omecamtiv mecarbil, systolic ejection time increased as previously reported and expected, while diastolic filling time was not reduced, nor were diastolic parameters worsened. Specifically, in patients receiving omecamtiv mecarbil E-wave velocity, E/A-ratio, and E/e' or e' were not significantly changed compared to placebo. There was a small increase in the duration of the IVRT, and in the PK group, TRV, an indicator of pulmonary pressure, improved significantly during treatment with omecamtiv mecarbil therapy.